title: Efficacy of a dose-intensified CHOP (Double-CHOP) regimen for peripheral             T-cell lymphomas.
abstract: Peripheral T-cell lymphomas (PTCLs) are a rare and heterogeneous group of             non-Hodgkin lymphomas, often resulting in poor prognoses. The CHOP chemotherapy             regimen, which includes cyclophosphamide, doxorubicin, vincristine and prednisone,             has been used previously to treat other types of lymphomas. Here, we examined             the efficacy and safety of a dose-intensified CHOP regimen (Double-CHOP), which             was followed by autologous stem-cell transplantation (ASCT) or high-dose methotrexate             (HDMTX), in PTCL patients. Twenty-eight PTCL patients, who received 3 courses             of Double-CHOP at our institution, were retrospectively studied from 1996 to 2012.             Patients with anaplastic lymphoma kinase-positive anaplastic large-cell lymphoma             (ALK+-ALCL) were excluded from this study. The median age of patients was 58 years             (range: 17-69). They had low-intermediate (n=11), high-intermediate (n=10) or             high (n=7) risk according to the International Prognostic Index (IPI). The overall             complete remission (CR) rate following Double-CHOP treatment was 68%. Of the CR             patients, 10 successfully tolerated a consolidated high-dose chemotherapy followed             by ASCT and 7 received HDMTX. A single case of treatment-related mortality was             recorded during the study. On a median 31-month follow-up, the estimated 3- or             5-year overall survival (OS) rates were 68 or 63%, respectively, while 3- or 5-year             relapse-free survival (RFS) rates after CR were 60 or 43%, respectively. Although             this study included elderly and excluded low-risk IPI and ALK+-ALCL patients,             OS results were superiorly favourable, indicating the efficacy of this Double-CHOP             regimen. However, an effective treatment strategy for refractory or relapsing             patients needs to be validated and established.
authors.affiliation: Department of Hematology and Rheumatology, Nihon University School of Medicine, Itabashi-ku, Tokyo, Japan. iriyama.noriyoshi@nihon-u.ac.jp
authors.forename: Noriyoshi
authors.initials: N
authors.lastname: Iriyama
authors.forename: Hiromichi
authors.initials: H
authors.lastname: Takahashi
authors.forename: Yoshihiro
authors.initials: Y
authors.lastname: Hatta
authors.forename: Katsuhiro
authors.initials: K
authors.lastname: Miura
authors.forename: Yujin
authors.initials: Y
authors.lastname: Kobayashi
authors.forename: Daisuke
authors.initials: D
authors.lastname: Kurita
authors.forename: Yukio
authors.initials: Y
authors.lastname: Hirabayashi
authors.forename: Atsuko
authors.initials: A
authors.lastname: Hojo
authors.forename: Hitomi
authors.initials: H
authors.lastname: Kodaira
authors.forename: Mai
authors.initials: M
authors.lastname: Yagi
authors.forename: Satomi
authors.initials: S
authors.lastname: Kiso
authors.forename: Yoshihito
authors.initials: Y
authors.lastname: Uchino
authors.forename: Masaru
authors.initials: M
authors.lastname: Nakagawa
authors.forename: Machiko
authors.initials: M
authors.lastname: Kusuda
authors.forename: Sumiko
authors.initials: S
authors.lastname: Kobayashi
authors.forename: Akira
authors.initials: A
authors.lastname: Horikoshi
authors.forename: Yoshimasa
authors.initials: Y
authors.lastname: Kura
authors.forename: Tetsuo
authors.initials: T
authors.lastname: Yamazaki
authors.forename: Umihiko
authors.initials: U
authors.lastname: Sawada
authors.forename: Jin
authors.initials: J
authors.lastname: Takeuchi
mesh_terms: D000293:Adolescent; D000328:Adult; D000368:Aged; D000740:Anemia / Q000139:chemically induced; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000008:administration & dosage* / Q000009:adverse effects; D003131:Combined Modality Therapy; D003520:Cyclophosphamide / Q000008:administration & dosage / Q000009:adverse effects; D018572:Disease-Free Survival; D004317:Doxorubicin / Q000008:administration & dosage / Q000009:adverse effects; D004334:Drug Administration Schedule; D005260:Female; D006801:Humans; D053208:Kaplan-Meier Estimate; D016411:Lymphoma, T-Cell, Peripheral / Q000188:drug therapy* / Q000628:therapy; D008297:Male; D008727:Methotrexate / Q000008:administration & dosage; D008875:Middle Aged; D009503:Neutropenia / Q000139:chemically induced; D011241:Prednisone / Q000008:administration & dosage / Q000009:adverse effects; D012189:Retrospective Studies; D012307:Risk Factors; D033581:Stem Cell Transplantation; D015996:Survival Rate; D013921:Thrombocytopenia / Q000139:chemically induced; D014182:Transplantation, Autologous; D014750:Vincristine / Q000008:administration & dosage / Q000009:adverse effects; D055815:Young Adult
chemical_list: D014750:Vincristine; D004317:Doxorubicin; D003520:Cyclophosphamide; D011241:Prednisone; D008727:Methotrexate